Inici › Leucèmia mieloide aguda › Nova Jersey › Edison
Assaigs clínics de Leucèmia mieloide aguda a Edison, NJ
20 estudis de Leucèmia mieloide aguda busquen participants en centres de Edison i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
ReclutantFase 1
- Rutgers Cancer Institute of New Jersey, New Brunswick · a 3 mi
- Memorial Sloan Kettering Basking Ridge, Basking Ridge · a 15 mi
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
ReclutantFase 2
- Rutgers Cancer Institute of New Jersey, New Brunswick · a 3 mi
- Memorial Sloan Kettering Basking Ridge, Basking Ridge · a 15 mi
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutantFase 2
- Rutgers Cancer Institute of New Jersey, New Brunswick · a 3 mi
- Memorial Sloan Kettering Basking Ridge, Basking Ridge · a 15 mi
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ReclutantFase 2
- Rutgers Cancer Institute of New Jersey, New Brunswick · a 3 mi
- Memorial Sloan Kettering Basking Ridge, Basking Ridge · a 15 mi
A Study of CRD3874-SI in People With Leukemia
ReclutantFase 1
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge · a 15 mi
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
ReclutantFase 2
- Rutgers Cancer Institute of New Jersey, New Brunswick · a 3 mi
- Memorial Sloan Kettering Basking Ridge, Basking Ridge · a 15 mi
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
ReclutantFase 2
- Rutgers Cancer Institute of New Jersey, New Brunswick · a 3 mi
- Memorial Sloan Kettering Basking Ridge, Basking Ridge · a 15 mi
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
ReclutantFase 3
- Saint Peter's University Hospital, New Brunswick · a 3 mi
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick · a 3 mi
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutantFase 1/2
- Saint Peter's University Hospital, New Brunswick · a 3 mi
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick · a 3 mi
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
ReclutantFase 3
- Rutgers Biomedical and Health Sciences, New Brunswick · a 3 mi
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
ReclutantFase 2
- Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge · a 15 mi
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutantEstudi observacional
- Robert Wood Johnson/Cancer Institute of New Jersey, New Brunswick · a 3 mi
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
ReclutantFase 1
- Memorial Sloan Kettering Basking Ridge, Basking Ridge · a 15 mi
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
ReclutantFase 1
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge · a 15 mi
A Study of Revumenib and Mezigdomide in People With Leukemia
ReclutantFase 1/2
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge · a 15 mi
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
ReclutantFase 1
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge · a 15 mi
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutantFase 1/2
- Rutgers Cancer Institute of New Jersey, New Brunswick · a 3 mi
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
ReclutantFase 1
- Rutgers Cancer Institute, New Brunswick · a 3 mi
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
ReclutantFase 1
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge · a 15 mi
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
ReclutantFase 2
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge · a 15 mi
Assaigs de Leucèmia mieloide aguda en altres ciutats
- Houston, TX85 estudis
- New York City, NY51 estudis
- Boston, MA44 estudis
- Baldwin Park, CA40 estudis
- Seattle, WA40 estudis
- Columbus, OH35 estudis
- Philadelphia, PA34 estudis
- Durham, NC33 estudis
- Atlanta, GA30 estudis
- Tampa, FL29 estudis
- Chicago, IL26 estudis
- Portland, OR25 estudis
Altres estudis a Edison
- Càncer de mama68 estudis
- Càncer de pulmó de cèl·lules no petites47 estudis
- Càncer (tots els tipus)33 estudis
- Càncer de pròstata29 estudis
- Càncer colorrectal23 estudis
- Càncer de pulmó23 estudis
- Mieloma múltiple22 estudis
- Càncer de bufeta21 estudis
- Càncer metastàtic20 estudis
- Càncer d'ovari20 estudis
- Càncer d'endometri19 estudis
- Carcinoma urotelial (de cèl·lules de transició)18 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.